GCGM
ODTX

General Catalyst Group Management’s Odyssey Therapeutics ODTX Stock Holding History

General Catalyst Group Management’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
+810,272
New +$14.2M 8.04% 5

Other funds holding ODTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

General Catalyst Group Management's ODTX Position: Q2 2026 in Review

General Catalyst Group Management opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 810,272 shares worth $15.2M. The stake represents 8.04% of the portfolio and ranks #5 among its holdings.

58 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

  • General Catalyst Group Management held 810,272 shares of Odyssey Therapeutics worth $15.2M as of Q2 2026.
  • Odyssey Therapeutics was a new General Catalyst Group Management position in Q2 2026.
  • Odyssey Therapeutics made up 8.04% of General Catalyst Group Management's portfolio in Q2 2026, its #5 holding.
  • 58 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.